Peptide Cheat Sheet
Quick reference for 115+ compounds — typical dosing, administration route, and half-life at a glance. Click any compound for the full wiki page.
Note: Dosing shown is from the first listed protocol per compound and may represent a typical or standard dose only. Full dosing details — including advanced protocols, loading phases, and timing — are on each compound's wiki page.
115 compounds
| Status | |||||
|---|---|---|---|---|---|
5-Amino-1MQFat Loss & Metabolic | Estimated 4–8 hours | Oral | 50–100 mg | Once to twice daily | — |
AdamaxCognitive Enhancement | Estimated 1-3 hours (short; peptide degradation) | SubcutaneousIntranasal (research) | 200-400 mcg per dose | Once daily or every other day | — |
AdipotideFat Loss & Metabolic | Estimated 2-4 hours | SubcutaneousIntravenous (research) | Not established for humans; primate studies used 0.1-1 mg/kg | Daily for 4 weeks (research protocol) | — |
AHK-CuSkin & Cosmetic | Hours (topical, variable by formulation) | TopicalScalp applicationSubcutaneous (research) | 0.01–0.1% concentration | Once or twice daily | — |
AICARAnti-Aging & Longevity | ~2–3 hours | SubQIV | 25–50 mg | 3–5 times per week | — |
Alpha-GPCCognitive Enhancement | ~4–6 hours | OralSubQ | 300–600 mg | 1–2x daily | — |
AOD-9604Fat Loss & Metabolic | 30-45 minutes injectable; longer with nasal spray formulation | SubQNasalOral | 300-600 mcg | Once daily | — |
ARA-290Immune Support | ~2–4 hours (SC administration) | SubQ | 4 mg (fixed dose) | Once daily | — |
ArgirelineSkin & Cosmetic | N/A — topical application; effect duration linked to formulation contact time | Topical | 5–10% concentration | Twice daily | — |
BPC-157Recovery & Repair | 4–6 hours | SubQIMOral | 200–500 mcg | Once daily | — |
BronchogenAnti-Aging & Longevity | Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting | SubQOral | 10 mg per day | Daily for 10–30 days | — |
CagrilintideGLP-1 / Weight Loss Agonists | ~7–10 days | SubQ | 0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg | Once weekly | — |
CardiogenAnti-Aging & Longevity | Short (minutes); gene-regulatory effects persist longer | SubQOral | 10 mg per day | Daily for 10–30 days | — |
CarnosineAnti-Aging & Longevity | ~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis) | OralTopical | 1,000–2,000 mg | Once to twice daily with meals | — |
CartalaxAnti-Aging & Longevity | Short (minutes); gene-regulatory effects are sustained | SubQOral | 10 mg per day | Daily for 10–30 days | — |
CerebrolysinCognitive Enhancement | Variable for the complex; individual peptide fractions: minutes to hours | IVIM | 5–10 mL | Daily for 10–20 days | — |
CerebrolysinCognitive Enhancement | Minutes (IV), but neuroplasticity effects persist for weeks | IVIM | 5–10 ml | Daily for 10–20 days | — |
ChonlutenAnti-Aging & Longevity | Short (minutes for the peptide); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
CJC-1295Growth Hormone Peptides | ~30 minutes (No DAC) / 6–8 days (with DAC) | SubQ | 100 mcg | Once daily, before bed | — |
Collagen PeptidesSkin & Cosmetic | N/A — food-derived; absorbed peptides circulate for hours, depot accumulation in tissues | Oral | 10–15 g | Once daily | — |
CortagenAnti-Aging & Longevity | Short peptide half-life; gene regulatory effects persist beyond peptide clearance | SubQIMOral | 10 mg SC or IM daily | Once daily | — |
Decapeptide-12Skin & Cosmetic | Not applicable (topical) | Topical | 5 ppm (0.0005%) concentration | Twice daily (AM and PM) | — |
DermorphinRecovery & Repair | Estimated 30-60 minutes (longer than endorphins due to D-Ala) | Subcutaneous (research)Intrathecal (research)Intranasal (research) | Not established for human use; research doses vary widely | Not established | — |
DihexaCognitive Enhancement | Unknown (limited pharmacokinetic data) | OralSubQTopical | 5–10 mg | Daily | — |
DihexaCognitive Enhancement | Long CNS retention due to high lipophilicity; exact half-life in humans not established | OralSubQTopical | 1–4 mg (oral) or 1–2 mg (SC) | 3–5x per week | — |
DS5Sleep Optimization | Estimated 30-60 minutes (peptide degradation) | SubcutaneousIntranasal (research) | 200-500 mcg per dose | Once nightly | — |
DSIPSleep Optimization | ~30–60 minutes; however downstream sleep effects last 4–6 hours | SubQIVNasal | 100–400 mcg | Once nightly | — |
DulaglutideGLP-1 / Weight Loss Agonists | ~5 days | SubQ | 0.75 mg → 1.5 mg | Once weekly | — |
EloralintideGLP-1 / Weight Loss Agonists | ~7 days (estimated, long-acting design) | SubQ | Under investigation in Phase 1/2 trials | Once weekly | — |
EnclomipheneGLP-1 / Weight Loss Agonists | 5-7 days (long half-life; accumulates) | Oral | 12.5-25 mg per day | Once daily or every other day | — |
EpithalonAnti-Aging & Longevity | 2–4 hours | SubQSL | 5–10 mg total per cycle | 0.5–1 mg daily | — |
ExenatideGLP-1 / Weight Loss Agonists | ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release | SubQ | 5 mcg, titrate to 10 mcg | Twice daily | — |
FollistatinAnabolic & IGF | ~3–5 hours (endogenous form) | IMSubQ | 50–100 mcg per injection site | Every other day or 2–3x per week | — |
Follistatin 315Anabolic & IGF | ~3–5 hours (longer systemic circulation vs FST-344) | SubQIM | No established human dosing protocol | Research use only | — |
Follistatin 344Anabolic & IGF | ~24–36 hours | SubQIM | 100 mcg | Once daily | — |
FOXO4-DRIAnti-Aging & Longevity | Estimated 2-4 hours (D-amino acid confers resistance to proteolysis) | SubcutaneousIntraperitoneal (research) | 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg | 3 consecutive days per cycle | — |
GHKSkin & Cosmetic | Extremely short as free peptide; tissue binding extends local effects | SubQTopicalOral | 100–500 mcg | Daily or 5x per week | — |
GHK-CuSkin & Cosmetic | 2–4 hours | SubQTopical | 1–3 mg | 3–5 times per week | — |
GHRP-2Growth Hormone Peptides | 15–60 minutes | SubQNasal | 100–300 mcg | 2–3 times daily | — |
GHRP-6Growth Hormone Peptides | 15–60 minutes | SubQNasal | 100–300 mcg | 2–3 times daily | — |
GlutathioneAnti-Aging & Longevity | Minutes to hours depending on route; IV half-life approximately 10-30 minutes | Oral (liposomal preferred)SublingualIntravenousNebulized/inhaledTopical | 250-1000 mg per day | Once or twice daily | — |
GonadorelinSexual Health & Libido | ~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization | SubQNasal | 100 mcg | Twice daily (every 12 hours) | — |
HexarelinGrowth Hormone Peptides | ~70 minutes | SubQ | 100–200 mcg | 2–3 times daily | — |
HGH Fragment 176-191Fat Loss & Metabolic | ~30 minutes | SubQ | 250–500 mcg | 1–3 times daily | — |
HumaninAnti-Aging & Longevity | ~4–8 hours (HNG) | SubQ | 2–8 mg | 3–5 times per week | — |
IGF-1 DESAnabolic & IGF | ~20–30 minutes (very short — designed for local action) | IMSubQ | 20–50 mcg per injection site | Once daily, post-workout | — |
IGF-1 LR3Anabolic & IGF | 20–30 hours | SubQIM | 40–80 mcg | Once daily or split twice daily | — |
IpamorelinGrowth Hormone Peptides | 2 hours | SubQ | 100–300 mcg | Once to twice daily | — |
Kisspeptin-10Sexual Health & Libido | ~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development | SubQIV | 50–500 mcg | Once daily to every other day | — |
KPVImmune Support | Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades | OralSubQTopical | 500 mcg – 1 mg | Once to twice daily | — |
Larazotide AcetateRecovery & Repair | Local gut action; minimal systemic exposure | Oral | 0.5-2 mg | 3x daily | — |
LeuprolideSexual Health & Libido | ~3 hours (SC/IM), but depot formulations last 1–12 months | SubQIM | 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly | Per depot schedule | — |
LiraglutideGLP-1 / Weight Loss Agonists | ~13 hours (once-daily dosing) | SubQ | Start 0.6 mg, titrate to 3 mg | Once daily | — |
LivagenAnti-Aging & Longevity | Short (minutes); gene-regulatory effects are sustained | SubQOral | 10 mg per day | Daily for 10–30 days | — |
LL-37Immune Support | Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance | SubQTopicalNasal | 100–300 mcg | 2–3x per week | — |
MatrixylSkin & Cosmetic | N/A — topical; sustained signaling effects on fibroblasts persist beyond single application | Topical | 3–8% concentration | Once or twice daily | — |
MazdutideGLP-1 / Weight Loss Agonists | ~7 days | SubQ | 1.5 mg → 3 mg → 4.5 mg → 6 mg | Once weekly | — |
Melanotan 1Skin & Cosmetic | ~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months | SubQ | 0.5–1 mg | Daily until desired color achieved, then maintenance | — |
Melanotan IISexual Health & Libido | 1–2 hours | SubQ | 0.25–0.5 mg | Once daily | — |
MGF (Mechano Growth Factor)Anabolic & IGF | Native MGF: minutes. PEG-MGF: ~3 days | SubQIM | 200–400 mcg | 1–2 times per week | — |
MK-677 (Ibutamoren)Growth Hormone Peptides | 24 hours | Oral | 10–25 mg | Once daily | — |
MOTS-cAnti-Aging & Longevity | Estimated 1–2 hours | SubQ | 5–15 mg | 3–5 times per week | — |
NAD+Anti-Aging & Longevity | Varies by route; IV provides direct cellular delivery | IVSubQOral | 500–1000 mg | Daily for 4–10 days (loading), then monthly maintenance | — |
Nonapeptide-1Skin & Cosmetic | Not applicable (topical) | Topical | 0.05–0.5% concentration in formulation | Twice daily | — |
NoopeptCognitive Enhancement | ~5–10 minutes but metabolite (CPG) effects last hours | OralSLNasal | 10–30 mg | 1–2x daily | — |
OrforglipronGLP-1 / Weight Loss Agonists | ~12 hours (once-daily oral dosing) | Oral | 12 mg → 24 mg → 36 mg → 45 mg | Once daily | — |
OvagenAnti-Aging & Longevity | Short (minutes); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
OxytocinCognitive Enhancement | ~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer) | NasalSubQIV | 20–40 IU | As needed (not daily long-term) | — |
P21Cognitive Enhancement | Not well characterized; likely short, but neurogenic effects persist long after administration | SubQNasal | 100–500 mcg | Once daily | — |
Pal-AHKSkin & Cosmetic | Extended (lipid depot effect in stratum corneum) | Topical | 0.01–0.05% in formulation | Once or twice daily | — |
Pal-GHKSkin & Cosmetic | Extended (lipid depot in stratum corneum) | Topical | 0.005–0.1% in formulation | Once or twice daily | — |
Palmitoyl Dipeptide-6Skin & Cosmetic | Not applicable (topical) | Topical | 0.005–0.05% in formulation | Once or twice daily | — |
Palmitoyl Tetrapeptide-7Skin & Cosmetic | Topical penetration-dependent; effects last hours to days | Topical | 2-5 ppm concentration in formulation | Twice daily | — |
PancragenAnti-Aging & Longevity | Short (minutes); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
PE-22-28Cognitive Enhancement | Relatively short; CNS effects may persist due to neurogenic mechanisms | SubQNasal | 200–400 mcg | Once daily | — |
PEG-MGFAnabolic & IGF | ~3 days (due to PEGylation) | SubQ | 200–400 mcg | 2–3x per week | — |
Pentapeptide-18Skin & Cosmetic | Not applicable (topical) | Topical | 0.005–0.05% in formulation | Twice daily | — |
PGPIPNImmune Support | Estimated 30-120 minutes (peptide degradation) | OralSubcutaneous (research) | 200-500 mg per day | Once or twice daily | — |
PinealonCognitive Enhancement | Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist | SubQOralNasal | 5–10 mg (oral) or 50–100 mcg (SC) | Once daily for 10 days | — |
PNC-27Immune Support | Not well established; estimated minutes to hours | Intravenous (research)Intraperitoneal (research) | Not established for humans; research doses vary by cell line and model | Not established for human use | — |
ProstamaxAnti-Aging & Longevity | Short (minutes); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
PT-141 (Bremelanotide)Sexual Health & Libido | 2–3 hours | SubQ | 0.5–1.75 mg | As needed (not daily) | — |
RetatrutideGLP-1 / Weight Loss Agonists | ~10–12 days | SubQ | 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg | Once weekly | — |
SelankCognitive Enhancement | Minutes (but effects persist for hours) | SubQNasal | 250–500 mcg | 1–3 times daily | — |
SemaglutideGLP-1 / Weight Loss Agonists | ~7 days | SubQOral | 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg | Once weekly, subcutaneous | — |
SemaglutideGLP-1 / Weight Loss Agonists | ~7 days (once-weekly dosing possible) | SubQOral | Titrate from 0.25 mg to 2.4 mg | Once weekly SC injection | — |
SemaxCognitive Enhancement | Minutes (but effects persist for hours via BDNF induction) | NasalSubQ | 0.25–1 mg (250–1000 mcg) | 1–2 times daily | — |
SermorelinGrowth Hormone Peptides | 10–20 minutes | SubQ | 200–500 mcg | 5–7 days per week | — |
SLU-PP-332Recovery & Repair | Not established in humans; rodent pharmacokinetics suggest hours | Oral (research)Subcutaneous (research) | Not established for humans; rodent studies used ~100 mg/kg/day | Once daily in rodent studies | — |
SNAP-8Skin & Cosmetic | N/A — topical application; local effect duration depends on formulation | Topical | 3–10% concentration in formulation | 1–2x daily | — |
Somatropin (HGH)Growth Hormone Peptides | 2-3 hours (subcutaneous); 20-30 minutes (intravenous) | SubcutaneousIntramuscular (less common) | 0.15-0.3 mg/day (adults); titrated to IGF-1 levels | Once daily | — |
SpermidineAnti-Aging & Longevity | ~30–60 minutes, but gut bacteria produce it continuously; supplementation raises tissue levels over weeks | Oral | 1–5 mg | Once daily | — |
SS-31 (Elamipretide)Anti-Aging & Longevity | ~2–5 hours | SubQ | 5–10 mg | Daily to several times per week | — |
SurvodutideGLP-1 / Weight Loss Agonists | ~7 days | SubQ | 0.6 mg → 2.4 mg → 4.8 mg → 6 mg | Once weekly | — |
Syn-AkeSkin & Cosmetic | Not applicable (topical; effect duration hours) | Topical | 0.01–0.1% (4–8 mg/g in clinical studies) | Twice daily | — |
Syn-CollSkin & Cosmetic | Extended (lipid depot in stratum corneum) | Topical | 0.005-0.05% in formulation | Once or twice daily | — |
TB-500Recovery & Repair | 2–3 hours | SubQIM | 2–2.5 mg | Twice weekly | — |
TeduglutideRecovery & Repair | ~2 hours; once-daily dosing due to gut-specific residence | SubQ | 0.05 mg/kg/day | Once daily | — |
TesamorelinGrowth Hormone Peptides | ~26 minutes | SubQ | 2 mg | Once daily | — |
TesofensineFat Loss & Metabolic | 8-10 days (exceptionally long; accumulates over weeks) | Oral | 0.25-0.5 mg per day | Once daily | — |
TestagenAnti-Aging & Longevity | Short (minutes); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
ThymagenImmune Support | Short (minutes); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
ThymalinImmune Support | Not well characterized as a complex extract; individual peptides have varying kinetics | SubQIM | 10 mg IM or SC daily | Once daily | — |
Thymosin Alpha-1Immune Support | 2–3 hours | SubQ | 0.8–1.6 mg | Twice weekly | — |
Thymosin Alpha-1Immune Support | ~2 hours (SC injection) | SubQ | 1.6 mg | 2x per week | — |
Thymosin Beta-4Recovery & Repair | Not well characterized; likely similar to TB-500 (~1–2 hours) | SubQIM | 5–10 mg | 2x per week (loading), then 1x per week (maintenance) | — |
ThymulinImmune Support | ~30 minutes active half-life | SubQ | 20-30 mcg | 10 days per month (Khavinson protocol) | — |
TirzepatideGLP-1 / Weight Loss Agonists | ~5 days | SubQ | 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg | Once weekly, subcutaneous | — |
Tripeptide-29Skin & Cosmetic | Not applicable (topical) | Topical | 0.01-0.1% in formulation | Once or twice daily | — |
TriptorelinSexual Health & Libido | Depot forms: weeks to months; aqueous: 6-8 hours | SubQIM | 100 mcg | Single injection | — |
VesiluteAnti-Aging & Longevity | Short (minutes); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
VesugenAnti-Aging & Longevity | Short (minutes); sustained gene-regulatory effects | SubQOral | 10 mg per day | Daily for 10–30 days | — |
VialoxSkin & Cosmetic | Not applicable (topical; effect duration hours) | Topical | 0.005-0.05% in formulation | Twice daily | — |
VilonImmune Support | Very short as a free dipeptide; effects mediated via gene regulation | SubQOral | 1–2 mg SC daily or 5–10 mg oral daily | Once daily | — |
VIPImmune Support | ~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects | NasalSubQIV | 50 mcg (4 sprays of 12.5 mcg each) | 4x daily | — |
5-Amino-1MQFat Loss & Metabolic
- Half-life
- Estimated 4–8 hours
- Route
- Oral
- Typical dose
- 50–100 mg
- Frequency
- Once to twice daily
AdamaxCognitive Enhancement
- Half-life
- Estimated 1-3 hours (short; peptide degradation)
- Route
- Subcutaneous
- Typical dose
- 200-400 mcg per dose
- Frequency
- Once daily or every other day
AdipotideFat Loss & Metabolic
- Half-life
- Estimated 2-4 hours
- Route
- Subcutaneous
- Typical dose
- Not established for humans; primate studies used 0.1-1 mg/kg
- Frequency
- Daily for 4 weeks (research protocol)
AHK-CuSkin & Cosmetic
- Half-life
- Hours (topical, variable by formulation)
- Route
- Topical
- Typical dose
- 0.01–0.1% concentration
- Frequency
- Once or twice daily
AICARAnti-Aging & Longevity
- Half-life
- ~2–3 hours
- Route
- SubQ
- Typical dose
- 25–50 mg
- Frequency
- 3–5 times per week
Alpha-GPCCognitive Enhancement
- Half-life
- ~4–6 hours
- Route
- Oral
- Typical dose
- 300–600 mg
- Frequency
- 1–2x daily
AOD-9604Fat Loss & Metabolic
- Half-life
- 30-45 minutes injectable; longer with nasal spray formulation
- Route
- SubQ
- Typical dose
- 300-600 mcg
- Frequency
- Once daily
ARA-290Immune Support
- Half-life
- ~2–4 hours (SC administration)
- Route
- SubQ
- Typical dose
- 4 mg (fixed dose)
- Frequency
- Once daily
ArgirelineSkin & Cosmetic
- Half-life
- N/A — topical application; effect duration linked to formulation contact time
- Route
- Topical
- Typical dose
- 5–10% concentration
- Frequency
- Twice daily
BPC-157Recovery & Repair
- Half-life
- 4–6 hours
- Route
- SubQ
- Typical dose
- 200–500 mcg
- Frequency
- Once daily
BronchogenAnti-Aging & Longevity
- Half-life
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
CagrilintideGLP-1 / Weight Loss Agonists
- Half-life
- ~7–10 days
- Route
- SubQ
- Typical dose
- 0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
- Frequency
- Once weekly
CardiogenAnti-Aging & Longevity
- Half-life
- Short (minutes); gene-regulatory effects persist longer
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
CarnosineAnti-Aging & Longevity
- Half-life
- ~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis)
- Route
- Oral
- Typical dose
- 1,000–2,000 mg
- Frequency
- Once to twice daily with meals
CartalaxAnti-Aging & Longevity
- Half-life
- Short (minutes); gene-regulatory effects are sustained
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
CerebrolysinCognitive Enhancement
- Half-life
- Variable for the complex; individual peptide fractions: minutes to hours
- Route
- IV
- Typical dose
- 5–10 mL
- Frequency
- Daily for 10–20 days
CerebrolysinCognitive Enhancement
- Half-life
- Minutes (IV), but neuroplasticity effects persist for weeks
- Route
- IV
- Typical dose
- 5–10 ml
- Frequency
- Daily for 10–20 days
ChonlutenAnti-Aging & Longevity
- Half-life
- Short (minutes for the peptide); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
CJC-1295Growth Hormone Peptides
- Half-life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- Route
- SubQ
- Typical dose
- 100 mcg
- Frequency
- Once daily, before bed
Collagen PeptidesSkin & Cosmetic
- Half-life
- N/A — food-derived; absorbed peptides circulate for hours, depot accumulation in tissues
- Route
- Oral
- Typical dose
- 10–15 g
- Frequency
- Once daily
CortagenAnti-Aging & Longevity
- Half-life
- Short peptide half-life; gene regulatory effects persist beyond peptide clearance
- Route
- SubQ
- Typical dose
- 10 mg SC or IM daily
- Frequency
- Once daily
Decapeptide-12Skin & Cosmetic
- Half-life
- Not applicable (topical)
- Route
- Topical
- Typical dose
- 5 ppm (0.0005%) concentration
- Frequency
- Twice daily (AM and PM)
DermorphinRecovery & Repair
- Half-life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Route
- Subcutaneous (research)
- Typical dose
- Not established for human use; research doses vary widely
- Frequency
- Not established
DihexaCognitive Enhancement
- Half-life
- Unknown (limited pharmacokinetic data)
- Route
- Oral
- Typical dose
- 5–10 mg
- Frequency
- Daily
DihexaCognitive Enhancement
- Half-life
- Long CNS retention due to high lipophilicity; exact half-life in humans not established
- Route
- Oral
- Typical dose
- 1–4 mg (oral) or 1–2 mg (SC)
- Frequency
- 3–5x per week
DS5Sleep Optimization
- Half-life
- Estimated 30-60 minutes (peptide degradation)
- Route
- Subcutaneous
- Typical dose
- 200-500 mcg per dose
- Frequency
- Once nightly
DSIPSleep Optimization
- Half-life
- ~30–60 minutes; however downstream sleep effects last 4–6 hours
- Route
- SubQ
- Typical dose
- 100–400 mcg
- Frequency
- Once nightly
DulaglutideGLP-1 / Weight Loss Agonists
- Half-life
- ~5 days
- Route
- SubQ
- Typical dose
- 0.75 mg → 1.5 mg
- Frequency
- Once weekly
EloralintideGLP-1 / Weight Loss Agonists
- Half-life
- ~7 days (estimated, long-acting design)
- Route
- SubQ
- Typical dose
- Under investigation in Phase 1/2 trials
- Frequency
- Once weekly
EnclomipheneGLP-1 / Weight Loss Agonists
- Half-life
- 5-7 days (long half-life; accumulates)
- Route
- Oral
- Typical dose
- 12.5-25 mg per day
- Frequency
- Once daily or every other day
EpithalonAnti-Aging & Longevity
- Half-life
- 2–4 hours
- Route
- SubQ
- Typical dose
- 5–10 mg total per cycle
- Frequency
- 0.5–1 mg daily
ExenatideGLP-1 / Weight Loss Agonists
- Half-life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Route
- SubQ
- Typical dose
- 5 mcg, titrate to 10 mcg
- Frequency
- Twice daily
FollistatinAnabolic & IGF
- Half-life
- ~3–5 hours (endogenous form)
- Route
- IM
- Typical dose
- 50–100 mcg per injection site
- Frequency
- Every other day or 2–3x per week
Follistatin 315Anabolic & IGF
- Half-life
- ~3–5 hours (longer systemic circulation vs FST-344)
- Route
- SubQ
- Typical dose
- No established human dosing protocol
- Frequency
- Research use only
Follistatin 344Anabolic & IGF
- Half-life
- ~24–36 hours
- Route
- SubQ
- Typical dose
- 100 mcg
- Frequency
- Once daily
FOXO4-DRIAnti-Aging & Longevity
- Half-life
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Route
- Subcutaneous
- Typical dose
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- 3 consecutive days per cycle
GHKSkin & Cosmetic
- Half-life
- Extremely short as free peptide; tissue binding extends local effects
- Route
- SubQ
- Typical dose
- 100–500 mcg
- Frequency
- Daily or 5x per week
GHK-CuSkin & Cosmetic
- Half-life
- 2–4 hours
- Route
- SubQ
- Typical dose
- 1–3 mg
- Frequency
- 3–5 times per week
GHRP-2Growth Hormone Peptides
- Half-life
- 15–60 minutes
- Route
- SubQ
- Typical dose
- 100–300 mcg
- Frequency
- 2–3 times daily
GHRP-6Growth Hormone Peptides
- Half-life
- 15–60 minutes
- Route
- SubQ
- Typical dose
- 100–300 mcg
- Frequency
- 2–3 times daily
GlutathioneAnti-Aging & Longevity
- Half-life
- Minutes to hours depending on route; IV half-life approximately 10-30 minutes
- Route
- Oral (liposomal preferred)
- Typical dose
- 250-1000 mg per day
- Frequency
- Once or twice daily
GonadorelinSexual Health & Libido
- Half-life
- ~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
- Route
- SubQ
- Typical dose
- 100 mcg
- Frequency
- Twice daily (every 12 hours)
HexarelinGrowth Hormone Peptides
- Half-life
- ~70 minutes
- Route
- SubQ
- Typical dose
- 100–200 mcg
- Frequency
- 2–3 times daily
HGH Fragment 176-191Fat Loss & Metabolic
- Half-life
- ~30 minutes
- Route
- SubQ
- Typical dose
- 250–500 mcg
- Frequency
- 1–3 times daily
HumaninAnti-Aging & Longevity
- Half-life
- ~4–8 hours (HNG)
- Route
- SubQ
- Typical dose
- 2–8 mg
- Frequency
- 3–5 times per week
IGF-1 DESAnabolic & IGF
- Half-life
- ~20–30 minutes (very short — designed for local action)
- Route
- IM
- Typical dose
- 20–50 mcg per injection site
- Frequency
- Once daily, post-workout
IGF-1 LR3Anabolic & IGF
- Half-life
- 20–30 hours
- Route
- SubQ
- Typical dose
- 40–80 mcg
- Frequency
- Once daily or split twice daily
IpamorelinGrowth Hormone Peptides
- Half-life
- 2 hours
- Route
- SubQ
- Typical dose
- 100–300 mcg
- Frequency
- Once to twice daily
Kisspeptin-10Sexual Health & Libido
- Half-life
- ~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
- Route
- SubQ
- Typical dose
- 50–500 mcg
- Frequency
- Once daily to every other day
KPVImmune Support
- Half-life
- Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
- Route
- Oral
- Typical dose
- 500 mcg – 1 mg
- Frequency
- Once to twice daily
Larazotide AcetateRecovery & Repair
- Half-life
- Local gut action; minimal systemic exposure
- Route
- Oral
- Typical dose
- 0.5-2 mg
- Frequency
- 3x daily
LeuprolideSexual Health & Libido
- Half-life
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- Route
- SubQ
- Typical dose
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- Frequency
- Per depot schedule
LiraglutideGLP-1 / Weight Loss Agonists
- Half-life
- ~13 hours (once-daily dosing)
- Route
- SubQ
- Typical dose
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once daily
LivagenAnti-Aging & Longevity
- Half-life
- Short (minutes); gene-regulatory effects are sustained
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
LL-37Immune Support
- Half-life
- Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
- Route
- SubQ
- Typical dose
- 100–300 mcg
- Frequency
- 2–3x per week
MatrixylSkin & Cosmetic
- Half-life
- N/A — topical; sustained signaling effects on fibroblasts persist beyond single application
- Route
- Topical
- Typical dose
- 3–8% concentration
- Frequency
- Once or twice daily
MazdutideGLP-1 / Weight Loss Agonists
- Half-life
- ~7 days
- Route
- SubQ
- Typical dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- Once weekly
Melanotan 1Skin & Cosmetic
- Half-life
- ~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
- Route
- SubQ
- Typical dose
- 0.5–1 mg
- Frequency
- Daily until desired color achieved, then maintenance
Melanotan IISexual Health & Libido
- Half-life
- 1–2 hours
- Route
- SubQ
- Typical dose
- 0.25–0.5 mg
- Frequency
- Once daily
MGF (Mechano Growth Factor)Anabolic & IGF
- Half-life
- Native MGF: minutes. PEG-MGF: ~3 days
- Route
- SubQ
- Typical dose
- 200–400 mcg
- Frequency
- 1–2 times per week
MK-677 (Ibutamoren)Growth Hormone Peptides
- Half-life
- 24 hours
- Route
- Oral
- Typical dose
- 10–25 mg
- Frequency
- Once daily
MOTS-cAnti-Aging & Longevity
- Half-life
- Estimated 1–2 hours
- Route
- SubQ
- Typical dose
- 5–15 mg
- Frequency
- 3–5 times per week
NAD+Anti-Aging & Longevity
- Half-life
- Varies by route; IV provides direct cellular delivery
- Route
- IV
- Typical dose
- 500–1000 mg
- Frequency
- Daily for 4–10 days (loading), then monthly maintenance
Nonapeptide-1Skin & Cosmetic
- Half-life
- Not applicable (topical)
- Route
- Topical
- Typical dose
- 0.05–0.5% concentration in formulation
- Frequency
- Twice daily
NoopeptCognitive Enhancement
- Half-life
- ~5–10 minutes but metabolite (CPG) effects last hours
- Route
- Oral
- Typical dose
- 10–30 mg
- Frequency
- 1–2x daily
OrforglipronGLP-1 / Weight Loss Agonists
- Half-life
- ~12 hours (once-daily oral dosing)
- Route
- Oral
- Typical dose
- 12 mg → 24 mg → 36 mg → 45 mg
- Frequency
- Once daily
OvagenAnti-Aging & Longevity
- Half-life
- Short (minutes); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
OxytocinCognitive Enhancement
- Half-life
- ~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
- Route
- Nasal
- Typical dose
- 20–40 IU
- Frequency
- As needed (not daily long-term)
P21Cognitive Enhancement
- Half-life
- Not well characterized; likely short, but neurogenic effects persist long after administration
- Route
- SubQ
- Typical dose
- 100–500 mcg
- Frequency
- Once daily
Pal-AHKSkin & Cosmetic
- Half-life
- Extended (lipid depot effect in stratum corneum)
- Route
- Topical
- Typical dose
- 0.01–0.05% in formulation
- Frequency
- Once or twice daily
Pal-GHKSkin & Cosmetic
- Half-life
- Extended (lipid depot in stratum corneum)
- Route
- Topical
- Typical dose
- 0.005–0.1% in formulation
- Frequency
- Once or twice daily
Palmitoyl Dipeptide-6Skin & Cosmetic
- Half-life
- Not applicable (topical)
- Route
- Topical
- Typical dose
- 0.005–0.05% in formulation
- Frequency
- Once or twice daily
Palmitoyl Tetrapeptide-7Skin & Cosmetic
- Half-life
- Topical penetration-dependent; effects last hours to days
- Route
- Topical
- Typical dose
- 2-5 ppm concentration in formulation
- Frequency
- Twice daily
PancragenAnti-Aging & Longevity
- Half-life
- Short (minutes); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
PE-22-28Cognitive Enhancement
- Half-life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- Route
- SubQ
- Typical dose
- 200–400 mcg
- Frequency
- Once daily
PEG-MGFAnabolic & IGF
- Half-life
- ~3 days (due to PEGylation)
- Route
- SubQ
- Typical dose
- 200–400 mcg
- Frequency
- 2–3x per week
Pentapeptide-18Skin & Cosmetic
- Half-life
- Not applicable (topical)
- Route
- Topical
- Typical dose
- 0.005–0.05% in formulation
- Frequency
- Twice daily
PGPIPNImmune Support
- Half-life
- Estimated 30-120 minutes (peptide degradation)
- Route
- Oral
- Typical dose
- 200-500 mg per day
- Frequency
- Once or twice daily
PinealonCognitive Enhancement
- Half-life
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- Route
- SubQ
- Typical dose
- 5–10 mg (oral) or 50–100 mcg (SC)
- Frequency
- Once daily for 10 days
PNC-27Immune Support
- Half-life
- Not well established; estimated minutes to hours
- Route
- Intravenous (research)
- Typical dose
- Not established for humans; research doses vary by cell line and model
- Frequency
- Not established for human use
ProstamaxAnti-Aging & Longevity
- Half-life
- Short (minutes); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
PT-141 (Bremelanotide)Sexual Health & Libido
- Half-life
- 2–3 hours
- Route
- SubQ
- Typical dose
- 0.5–1.75 mg
- Frequency
- As needed (not daily)
RetatrutideGLP-1 / Weight Loss Agonists
- Half-life
- ~10–12 days
- Route
- SubQ
- Typical dose
- 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
- Frequency
- Once weekly
SelankCognitive Enhancement
- Half-life
- Minutes (but effects persist for hours)
- Route
- SubQ
- Typical dose
- 250–500 mcg
- Frequency
- 1–3 times daily
SemaglutideGLP-1 / Weight Loss Agonists
- Half-life
- ~7 days
- Route
- SubQ
- Typical dose
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- Frequency
- Once weekly, subcutaneous
SemaglutideGLP-1 / Weight Loss Agonists
- Half-life
- ~7 days (once-weekly dosing possible)
- Route
- SubQ
- Typical dose
- Titrate from 0.25 mg to 2.4 mg
- Frequency
- Once weekly SC injection
SemaxCognitive Enhancement
- Half-life
- Minutes (but effects persist for hours via BDNF induction)
- Route
- Nasal
- Typical dose
- 0.25–1 mg (250–1000 mcg)
- Frequency
- 1–2 times daily
SermorelinGrowth Hormone Peptides
- Half-life
- 10–20 minutes
- Route
- SubQ
- Typical dose
- 200–500 mcg
- Frequency
- 5–7 days per week
SLU-PP-332Recovery & Repair
- Half-life
- Not established in humans; rodent pharmacokinetics suggest hours
- Route
- Oral (research)
- Typical dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- Frequency
- Once daily in rodent studies
SNAP-8Skin & Cosmetic
- Half-life
- N/A — topical application; local effect duration depends on formulation
- Route
- Topical
- Typical dose
- 3–10% concentration in formulation
- Frequency
- 1–2x daily
Somatropin (HGH)Growth Hormone Peptides
- Half-life
- 2-3 hours (subcutaneous); 20-30 minutes (intravenous)
- Route
- Subcutaneous
- Typical dose
- 0.15-0.3 mg/day (adults); titrated to IGF-1 levels
- Frequency
- Once daily
SpermidineAnti-Aging & Longevity
- Half-life
- ~30–60 minutes, but gut bacteria produce it continuously; supplementation raises tissue levels over weeks
- Route
- Oral
- Typical dose
- 1–5 mg
- Frequency
- Once daily
SS-31 (Elamipretide)Anti-Aging & Longevity
- Half-life
- ~2–5 hours
- Route
- SubQ
- Typical dose
- 5–10 mg
- Frequency
- Daily to several times per week
SurvodutideGLP-1 / Weight Loss Agonists
- Half-life
- ~7 days
- Route
- SubQ
- Typical dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Once weekly
Syn-AkeSkin & Cosmetic
- Half-life
- Not applicable (topical; effect duration hours)
- Route
- Topical
- Typical dose
- 0.01–0.1% (4–8 mg/g in clinical studies)
- Frequency
- Twice daily
Syn-CollSkin & Cosmetic
- Half-life
- Extended (lipid depot in stratum corneum)
- Route
- Topical
- Typical dose
- 0.005-0.05% in formulation
- Frequency
- Once or twice daily
TB-500Recovery & Repair
- Half-life
- 2–3 hours
- Route
- SubQ
- Typical dose
- 2–2.5 mg
- Frequency
- Twice weekly
TeduglutideRecovery & Repair
- Half-life
- ~2 hours; once-daily dosing due to gut-specific residence
- Route
- SubQ
- Typical dose
- 0.05 mg/kg/day
- Frequency
- Once daily
TesamorelinGrowth Hormone Peptides
- Half-life
- ~26 minutes
- Route
- SubQ
- Typical dose
- 2 mg
- Frequency
- Once daily
TesofensineFat Loss & Metabolic
- Half-life
- 8-10 days (exceptionally long; accumulates over weeks)
- Route
- Oral
- Typical dose
- 0.25-0.5 mg per day
- Frequency
- Once daily
TestagenAnti-Aging & Longevity
- Half-life
- Short (minutes); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
ThymagenImmune Support
- Half-life
- Short (minutes); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
ThymalinImmune Support
- Half-life
- Not well characterized as a complex extract; individual peptides have varying kinetics
- Route
- SubQ
- Typical dose
- 10 mg IM or SC daily
- Frequency
- Once daily
Thymosin Alpha-1Immune Support
- Half-life
- 2–3 hours
- Route
- SubQ
- Typical dose
- 0.8–1.6 mg
- Frequency
- Twice weekly
Thymosin Alpha-1Immune Support
- Half-life
- ~2 hours (SC injection)
- Route
- SubQ
- Typical dose
- 1.6 mg
- Frequency
- 2x per week
Thymosin Beta-4Recovery & Repair
- Half-life
- Not well characterized; likely similar to TB-500 (~1–2 hours)
- Route
- SubQ
- Typical dose
- 5–10 mg
- Frequency
- 2x per week (loading), then 1x per week (maintenance)
ThymulinImmune Support
- Half-life
- ~30 minutes active half-life
- Route
- SubQ
- Typical dose
- 20-30 mcg
- Frequency
- 10 days per month (Khavinson protocol)
TirzepatideGLP-1 / Weight Loss Agonists
- Half-life
- ~5 days
- Route
- SubQ
- Typical dose
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Once weekly, subcutaneous
Tripeptide-29Skin & Cosmetic
- Half-life
- Not applicable (topical)
- Route
- Topical
- Typical dose
- 0.01-0.1% in formulation
- Frequency
- Once or twice daily
TriptorelinSexual Health & Libido
- Half-life
- Depot forms: weeks to months; aqueous: 6-8 hours
- Route
- SubQ
- Typical dose
- 100 mcg
- Frequency
- Single injection
VesiluteAnti-Aging & Longevity
- Half-life
- Short (minutes); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
VesugenAnti-Aging & Longevity
- Half-life
- Short (minutes); sustained gene-regulatory effects
- Route
- SubQ
- Typical dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
VialoxSkin & Cosmetic
- Half-life
- Not applicable (topical; effect duration hours)
- Route
- Topical
- Typical dose
- 0.005-0.05% in formulation
- Frequency
- Twice daily
VilonImmune Support
- Half-life
- Very short as a free dipeptide; effects mediated via gene regulation
- Route
- SubQ
- Typical dose
- 1–2 mg SC daily or 5–10 mg oral daily
- Frequency
- Once daily
VIPImmune Support
- Half-life
- ~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
- Route
- Nasal
- Typical dose
- 50 mcg (4 sprays of 12.5 mcg each)
- Frequency
- 4x daily